---
title: "PAYS: Record revenue and margin expansion driven by dual growth engines and proprietary technology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296149194.md"
description: "Holding a leading U.S. plasma payments market share and rapidly scaling its patient affordability business, the company delivered 40.5% revenue growth and 107.3% adjusted EBITDA growth in FY2025. Proprietary technology, a capital-light model, and expanding margins underpin raised FY2026 guidance and a balanced, two-engine platform.Original document: Paysign, Inc. [PAYS] Slides Release — Aug. 17 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-17T21:40:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296149194.md)
  - [en](https://longbridge.com/en/news/296149194.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296149194.md)
---

# PAYS: Record revenue and margin expansion driven by dual growth engines and proprietary technology

Holding a leading U.S. plasma payments market share and rapidly scaling its patient affordability business, the company delivered 40.5% revenue growth and 107.3% adjusted EBITDA growth in FY2025. Proprietary technology, a capital-light model, and expanding margins underpin raised FY2026 guidance and a balanced, two-engine platform.

Original document: Paysign, Inc. \[PAYS\] Slides Release — Aug. 17 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PAYS.US](https://longbridge.com/en/quote/PAYS.US.md)

## Related News & Research

- [Paysign to present at Midwest IDEAS Investor Conference](https://longbridge.com/en/news/296226979.md)
- [GSA Capital Partners LLP Buys Shares of 119,578 Paysign, Inc. $PAYS](https://longbridge.com/en/news/296319049.md)
- [Paysign CFO Jeffery Bradford Baker disposes of 35,000 shares worth $441,637](https://longbridge.com/en/news/295976877.md)
- [PAYS: Record revenue, margin expansion, and raised outlook highlight robust Q2 2026 performance](https://longbridge.com/en/news/295007552.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)